Who is sponsoring NCT03042533?

NCT03042533 is sponsored by University of Washington.

What drugs are being tested in NCT03042533?

Interventions in NCT03042533: Conventional Compression, Standard Backslapping, Dynamic Locking with Backslapping.

What condition does NCT03042533 study?

NCT03042533 studies Closed Transverse Fracture of Shaft of Tibia.

Is NCT03042533 still recruiting?

NCT03042533 is currently terminated. Last updated 3 May 2024.

Are results published for NCT03042533?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-05-03 · How we verify

NCT03042533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Union Rate of Transverse Tibia Fracture

Terminated NA Results posted Last updated 3 May 2024

What this trial tests

NA trial testing Conventional Compression in Closed Transverse Fracture of Shaft of Tibia in 9 participants. Terminated before completion.

Timeline

1 February 2017

Primary endpoint
29 May 2018

29 May 2018

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	9
Start date	1 February 2017
Primary completion	29 May 2018
Estimated completion	29 May 2018
Sites	1 location across United States

Drugs / interventions tested

Conventional Compression
Standard Backslapping
Dynamic Locking with Backslapping

Conditions studied

Closed Transverse Fracture of Shaft of Tibia — all drugs for Closed Transverse Fracture of Shaft of Tibia →

Sponsor

University of Washington

Who can join

16 and older, any sex, with Closed Transverse Fracture of Shaft of Tibia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will compare the three methods of seating a tibial nail - Backslapping or Backslapping with Dynamic Locking or Internal Compression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03042533 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 3 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing